Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03024996 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 778
- Enrollment target
NCT03024996 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 778 participants.
The verdict
NCT03024996, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 778 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.
Interventions
- DRUG Atezolizumab
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 778 participants |
| Start Date | 2017-01-03 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03024996
The ClinicalTrials.gov registry entry for NCT03024996 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 778 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03024996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03024996 about?
NCT03024996 is a clinical study titled "A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy". This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.
What is the current status of trial NCT03024996?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 778 participants. The study started on 2017-01-03. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT03024996?
The interventions under investigation include: Atezolizumab (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT03024996?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.